ACCC National Oncology Conference

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.

During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, discusses some of the challenges he has encountered with chimeric antigen receptor T-cell therapy.

During a presentation at the Association of Community Cancer Centers&rsquo; 35th National Oncology Conference,&nbsp;Marc Matrana, MD, discussed the development of the Ochsner Health System&rsquo;s Precision Cancer Therapies Program to provide early phase clinical trials in the community setting across the state.<br /> &nbsp;

During a preconference presentation at the Association of Community Cancer Centers 35th National Oncology Conference in Phoenix, a panel of experts discussed the challenges they foresee with the wave of new biosimilar launches expected in 2019.

James L. Wade III, MD, FACP, FASCO, discusses the importance of clinical trials in the community.

In a presentation during the Association of Community Cancer Centers 35th National Oncology Conference (NOC) in Phoenix, Arizona, featured speaker Vicki Hess, RN, MS, discussed how oncology teams can become more resilient in the face of challenges.

Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.

Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to &ldquo;reflect, renew, and reignite&rdquo; in order to create a more resilient oncology team for the community.